To determine if MET-T1010I alters breast cancer pathophysiology, we compared its effects to MET-WT representing MET overexpression in breast cancer and to MET-Y1253D tyrosine kinase domain mutation representing an activated MET receptor. The gene discussed is MET; the disease is breast carcinoma.